Murray A. Raskind, MD

Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System (VA Puget Sound), Seattle, Washington, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle.

JCP
Dysregulation of Noradrenergic Activity
Academic Highlights

November 8, 2024

Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
, , , et al
JCP
Article

May 25, 2016

One alpha-1 noradrenergic antagonist drug has shown promise in treating PTSD-related sleep disturbances and nightmares, but it has a short half-life. Could the long half-life version of this type...
, , , et al
JCP
Letter to the Editor

January 15, 2010

,
JCP
Letter to the Editor

November 15, 2006

, , , et al
JCP
Original Research

July 16, 2002

, , , et al
JCP
Letter to the Editor

August 31, 2000

,
JCP
Original Research

July 31, 2000

, , , et al
JCP
Article

June 1, 1999

JCP
Original Research

May 1, 1999

, , , et al
JCP
Article

May 1, 1998

JCP
Article

March 1, 1998

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe